Effects of PD-1/PD-L1 on the malignant behavior of thyroid cancer cells through the TGF-β/Smad signaling pathway.
- 1Department of Nuclear Medicine, People's Hospital of Ningxia Hui Autonomous Region, Yinchuan, Ningxia Hui Autonomous Region 750011, P.R. China.
- 2Department of Nuclear Medicine, People's Hospital of Ningxia Hui Autonomous Region, Ningxia Medical University, Yinchuan, Ningxia Hui Autonomous Region 750011, P.R. China.
- 3Department of Oncology, People's Hospital of Ningxia Hui Autonomous Region, Yinchuan, Ningxia Hui Autonomous Region 750011, P.R. China.
Abstract
Papillary thyroid cancer (PTC) is the most common type of malignant tumor in the endocrine system, with an incidence rate that is increasing year by year. In addition, the mortality rate of advanced PTC is also on the rise, posing a threat to human health. Programmed cell death protein-1 (PD-1)/programmed death-ligand 1 (PD-L1) signaling has been reported to be abnormally expressed in PTC, while the possible effects and underlying mechanisms remain to be further explored. In the present study, the expression levels of PD-1 and PD-L1 were upregulated in clinical PTC tissues as well as TPC-1 and BCPAP cells as detected by reverse transcription-quantitative PCR and western blotting analysis. Notably, PD-1 expression in tissue samples may originate from both tumor cells and tumor-infiltrating immune cells, whereas PD-1 detected in cell lines solely represents tumor-intrinsic expression. Functionally, downregulation of PD-1 or PD-L1 notably inhibited the viability, proliferation and induced the apoptosis of TC cells, as measured by Cell Counting Kit-8, EdU, colony formation, flow cytometry and western blotting analysis. In addition, downregulation of PD-1 or PD-L1 markedly suppressed the migration, invasion and epithelial-mesenchymal transition progress of TC cells, as measured by wound healing and Transwell migration and invasion assays, as well as western blotting analysis. Furthermore, downregulation of PD-1 or PD-L1 inactivated the TGF-β/Smad signaling pathway. Exogenous TGF-β partially restored the effects of short hairpin (sh)-PD-1 or sh-PD-L1 on the viability, proliferation, apoptosis, migration, invasion and EMT progress of PTC cells. To conclude, the present study suggests PD-1/PD-L1 may represent potential therapeutic targets for the treatment of patients with PTC, though further studies across additional thyroid cancer subtypes are warranted.
Related
- Integrated single-cell transcriptomics reveals miR-941 targets CLDN4 to inhibit malignant progression of thyroid cancer through the PI3K/AKT signaling pathway.
- Acquired TRAIL Resistance Promotes Cancer Stemness and Malignant Behavior through CD44-SPHK1-STAT3 Signaling in Colorectal Cancer
- VGLL4 Suppresses Malignant Phenotypes of Clear Cell Renal Cell Carcinoma Cells Through Modulation of Hippo/YAP and Wnt/β-Catenin Signaling Pathways
- PEG10/TRIB3 axis is associated with malignant behavior and Notch-related signaling in oral squamous cell carcinoma cells
- NDUFS1 promotes malignant breast cancer behaviors through enhancement of mitochondrial respiration and PROX1/c-Myc signaling
BibTeX
@article{wang2026effects,
title = {{Effects of PD-1/PD-L1 on the malignant behavior of thyroid cancer cells through the TGF-β/Smad signaling pathway.}},
author = {Xueji Wang and Jing Wang and Wei Cui and Jingxia Wang and Xueyan Zhang and Bingliang Zhang},
journal = {Experimental and therapeutic medicine},
year = {2026},
month = sep,
doi = {10.3892/etm.2026.13317},
url = {https://europepmc.org/article/MED/42924029},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Effects of PD-1/PD-L1 on the malignant behavior of thyroid cancer cells through the TGF-β/Smad signaling pathway.
AU - Xueji Wang
AU - Jing Wang
AU - Wei Cui
AU - Jingxia Wang
AU - Xueyan Zhang
AU - Bingliang Zhang
PY - 2026
DA - 2026/09/29
JO - Experimental and therapeutic medicine
DO - 10.3892/etm.2026.13317
UR - https://europepmc.org/article/MED/42924029
AB - Papillary thyroid cancer (PTC) is the most common type of malignant tumor in the endocrine system, with an incidence rate that is increasing year by year. In addition, the mortality rate of advanced PTC is also on the rise, posing a threat to human health. Programmed cell death protein-1 (PD-1)/programmed death-ligand 1 (PD-L1) signaling has been reported to be abnormally expressed in PTC, while the possible effects and underlying mechanisms remain to be further explored. In the present study, the expression levels of PD-1 and PD-L1 were upregulated in clinical PTC tissues as well as TPC-1 and BCPAP cells as detected by reverse transcription-quantitative PCR and western blotting analysis. Notably, PD-1 expression in tissue samples may originate from both tumor cells and tumor-infiltrating immune cells, whereas PD-1 detected in cell lines solely represents tumor-intrinsic expression. Functionally, downregulation of PD-1 or PD-L1 notably inhibited the viability, proliferation and induced the apoptosis of TC cells, as measured by Cell Counting Kit-8, EdU, colony formation, flow cytometry and western blotting analysis. In addition, downregulation of PD-1 or PD-L1 markedly suppressed the migration, invasion and epithelial-mesenchymal transition progress of TC cells, as measured by wound healing and Transwell migration and invasion assays, as well as western blotting analysis. Furthermore, downregulation of PD-1 or PD-L1 inactivated the TGF-β/Smad signaling pathway. Exogenous TGF-β partially restored the effects of short hairpin (sh)-PD-1 or sh-PD-L1 on the viability, proliferation, apoptosis, migration, invasion and EMT progress of PTC cells. To conclude, the present study suggests PD-1/PD-L1 may represent potential therapeutic targets for the treatment of patients with PTC, though further studies across additional thyroid cancer subtypes are warranted.
SN - 1792-0981
SN - 1792-1015
ER -